Other cancer types that also had FGFR2 fusion but had much lower fusion rates included LUSC (0.41%), breast invasive carcinoma (BRCA) (0.28%), ovarian serous cystadenocarcinoma (OV) (0.17%), liver hepatocellular carcinoma (LIHC) (0.54%), and THCA (0.4%). This evidence concerns the gene FGFR2 and invasive breast carcinoma.